Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096870 | 0.80 | ALDH1A1 (0.34) | ALDH1A1KDM4ENSD2MAPTADORA2A | |
| SCHEMBL14923156 | 0.76 | LRRK2 (0.44) | PROKR1CYP1A2LRRK2ALDH1A1MAPT | |
| SCHEMBL5423132 | 0.76 | HTR2A (0.36) | CYP1A2LRRK2HTR2AHTR2CNPC1 | |
| SCHEMBL31239647 | 0.74 | LRRK2 (0.37) | CYP1A2LRRK2HTR2AHTR2CNPC1 | |
| SCHEMBL21379850 | 0.74 | LRRK2 (0.37) | CYP1A2LRRK2HTR2AHTR2CNPC1 | |
| SCHEMBL28177579 | 0.74 | LRRK2 (0.37) | PROKR1CYP1A2LRRK2ADORA2AADORA3 | |
| SCHEMBL26275972 | 0.72 | GAA (0.36) | CYP1A2LRRK2ALDH1A1HTR2AHTR2C | |
| SCHEMBL3725190 | 0.71 | HTR2A (0.36) | CYP1A2LRRK2HTR2AHTR2CGAA | |
| SCHEMBL26288474 | 0.71 | CYP1A2 (0.33) | CYP1A2LRRK2HTR2AHTR2CHSD11B1 | |
| SCHEMBL17373247 | 0.71 | GAA (0.35) | CYP1A2LRRK2ALDH1A1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332929-A | 3-amido-beta-carboline compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-27 | — | — | CN | disclosed |
| EP-2986608-B1 | ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H LUNDBECK AS (DK) | 2017-08-23 | — | — | EP | disclosed |
| US-9675594-B2 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2017-06-13 | — | — | US | disclosed |
| CN-105263930-B | As the aryl-pyrrolidine and pyridine derived compound of LRRK2 inhibitor | H.隆德贝克有限公司 | 2017-06-09 | — | — | CN | disclosed |
| US-20170020850-A1 | Arylpyrrolopyridine Derived Compounds as LRRK2 Inhibitors | H. Lundebck A/S (DK) | 2017-01-26 | — | — | US | disclosed |
| US-9499542-B2 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-11-22 | — | — | US | disclosed |
| US-20160102089-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-04-14 | — | — | US | disclosed |
| EP-2986608-A1 | ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. Lundbeck A/S (DK) | 2016-02-24 | — | — | EP | disclosed |
| CN-105263930-A | Arylpyrrolopyridine derived compounds as lrrk2 inhibitors | LUNDBECK & CO AS H | 2016-01-20 | — | — | CN | disclosed |
| WO-2014170248-A1 | ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315901-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020850-A1 | Arylpyrrolopyridine Derived Compounds as LRRK2 Inhibitors | LRRK2, PARK7, SNCA | PROKR1 2223/4885CYP1A2 2591/4885LRRK2 1/4885 |
| US-20160102089-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | LRRK2, PARK7, SNCA | PROKR1 1914/4885CYP1A2 2157/4885LRRK2 1/4885 |
| US-20140315901-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | LRRK2, PARK7, SNCA | PROKR1 2265/4885CYP1A2 2384/4885LRRK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.